JLL vs STRO · P/E 23, rev $23.43B vs rev $62.0M
Jones Lang LaSalle Incorporated (JLL) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported JLL revenue for 2024-12-31 was $23.43B. Net income was $546.8M. Revenue was up 12.9% from 2023-12-31 to 2024-12-31. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
JLL currently screens at market cap $12.12B and trailing P/E 23.0. STRO currently screens at market cap $470.8M.
Not investment advice. Open the JLL and STRO stock pages for the full models.
Not investment advice.